

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): May 11, 2010

**PRESTIGE BRANDS HOLDINGS, INC.**  
(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-32433**  
(Commission File Number)

**20-1297589**  
(IRS Employer Identification No.)

90 North Broadway, Irvington, New York 10533  
(Address of Principal Executive Offices)

(914) 524-6810  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
- 
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoint of Certain Officers; Compensatory Arrangements of Certain Officers.**

(d) On May 11, 2010, the Board of Directors of Prestige Brands Holdings, Inc. (the “Company”) appointed Charles Hinkaty to the Board of Directors. At this time, Mr. Hinkaty has not been appointed to any committees of the Board of Directors. A subsequent Form 8-K will be filed with the Securities and Exchange Commission upon Mr. Hinkaty's appointment to any committees of the Board of Directors.

**Item 7.01. Regulation FD Disclosure**

On May 17, 2010, the Company issued the press release that is furnished hereto as Exhibit 99.1 and incorporated by reference as if fully set forth herein announcing the matter described in Item 5.02 of this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

See Exhibit Index immediately following the signature page.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PRESTIGE BRANDS HOLDINGS, INC.**

Date: May 17, 2010

By: /s/ Eric S. Klee

Name: Eric S. Klee

Title: Secretary and General Counsel

---

## EXHIBIT INDEX

Exhibit	Description
99.1	Press Release dated May 17, 2010 announcing the appointment of Charles Hinkaty to Registrant's Board of Directors.

**CHARLES J. HINKATY APPOINTED TO PRESTIGE BRANDS HOLDINGS  
BOARD OF DIRECTORS**

Irvington, NY, May 17, 2010—Charles J. Hinkaty has been appointed to the Board of Directors of Prestige Brands Holdings, Inc. (NYSE-PBH), a consumer products company with a diversified portfolio of well-known brands in over-the-counter healthcare, household cleaning and personal care categories.

Mr. Hinkaty brings almost forty years of executive experience in consumer products to the board. Most recently, he served as President and CEO of Del Laboratories, Inc. where he was for twenty-three years. His background also includes a long career with Bristol-Myers Squibb, Inc. in marketing, acquisitions, licensing, strategic planning, and business development.

“Charlie has a wealth of experience in the over-the-counter industry,” said Matthew M. Mannelly, President and CEO of Prestige Brands. “He adds a breadth of valuable experience to our board in a number of key areas. We look forward to his counsel, and are delighted to welcome him to the board.”

His past professional affiliations include having served as Chairman of the Consumer Healthcare Products Association, one of the industry’s leading trade organizations. Mr. Hinkaty holds a B.S and an M.S. from Polytechnic Institute of New York University, and currently serves as a Trustee.

Among the products marketed by Prestige Brands are Comet® cleanser, Chloraseptic® sore throat treatment, Compound W® wart remover, Clear Eyes® eye care products, and the Little Remedies® line of pediatric over-the-counter healthcare products.

Contact: Dean Siegal, Director, Investor Relations & Communications  
914-524-6819